Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

I-Mab’s Bispecific Antibody Joined by BMS’s PD-1 in Gastric Cancer Trial

publication date: Jun 6, 2024

I-Mab , now a US company since selling off its China assets earlier this year, announced plans to form a clinical trial collaboration with Bristol Myers Squibb that will combine I-Mab’s givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with BMS’s PD-1, nivolumab. The Phase I trial will examine the combination as a first-line therapy for advanced Claudin 18.2-positive gastric and esophageal cancers. Patients will also receive chemotherapy (FOLFOX or CAPOX). BMW will supply nivolumab to participants in the trial. I-Mab is jointly developing givastomig with ABL Bio of Korea. More details....

Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 298380)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital